Why Is LIQUIDIA CORP (LQDA) Stock Up Today?

Liquidia Corporation (LQDA) shares rose 5.56% to $58.28 on Tuesday, driven by a series of positive analyst actions centered on the commercial rollout of its lung-disease therapy, Yutrepia. The stock gained momentum after Raymond James upgraded the rating to Strong Buy from Outperform, citing strong commercial performance for the drug.

What Happened

Raymond James initiated coverage with a Strong Buy rating, highlighting the successful launch of Yutrepia. This move was followed by Wells Fargo maintaining its rating while raising the price target to $40.00. Additionally, BofA raised its price target from $42 to $54. Other firms, including Needham and BTIG, also raised their price targets to $66 and $87, respectively. The company is scheduled to present at the 2026 Jefferies Global Healthcare Conference.

What The Data Shows

The stock printed 21 fresh 52-week highs and one fresh 52-week low on November 12, 2026. Over the last eight sessions, the stock climbed 31.9%, moving from $41.85 to $55.21. The 52-week range stands between $22.31 and $93.61. Fundamentals show a market cap of $4.6 billion with revenue up 798.4% year-over-year, though the company remains unprofitable with a trailing twelve-month EPS of -1.07 and a net margin of -15.1%. Intraday, the stock opened at $55.01, hit a session low of $53.80 at 8:55 AM ET, and reached a high of $58.50 at 12:25 PM ET. Volume so far is 0.8 million shares, which is 0.3 times the three-month daily average. Recent insider activity includes 17 sells totaling $25.8 million over the last 90 days, with no buys recorded.

What To Watch

Investors will monitor the upcoming presentation at the 2026 Jefferies Global Healthcare Conference for further updates on Yutrepia's commercial trajectory.